Insider · CIK 0001055624
SPRINGER TIMOTHY A
directorowner
Files at RNAC (Cartesian Therapeutics, Inc.), TECX (Tectonic Therapeutic, Inc.). First filing Oct 24, 2024, latest Mar 20, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
5 / 0
$20M bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 45Moderate | buy | RNAC Cartesian Therapeutics, Inc. | $1.4M | 89,863 | +1% | - | |
| 30Weak | buy | RNAC Cartesian Therapeutics, Inc. | $366k | 20,967 | +0% | - | |
| 40Moderate | buy | RNAC Cartesian Therapeutics, Inc. | $965k | 52,189 | +1% | - | |
| 43Moderate | buy | RNAC Cartesian Therapeutics, Inc. | $7.4M | 431,940 | +5% | - | |
| 43Moderate | buy | TECX Tectonic Therapeutic, Inc. | $10M | 300,000 | +8% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 18, 2025 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +14,740 | $14.42 | $213k | 8,546,202 | Mar 20, 2025 |
| Mar 19, 2025 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +20,234 | $14.97 | $303k | 8,566,436 | Mar 20, 2025 |
| Mar 20, 2025 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +54,889 | $15.59 | $856k | 8,621,325 | Mar 20, 2025 |
| Jan 13, 2025 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +7,962 | $16.86 | $134k | 8,518,457 | Jan 15, 2025 |
| Jan 13, 2025 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +8,983 | $17.78 | $160k | 8,527,440 | Jan 15, 2025 |
| Jan 14, 2025 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +4,022 | $18.00 | $72k | 8,531,462 | Jan 15, 2025 |
| Jan 2, 2025 | RNAC Cartesian Therapeutics, Inc. | AGrant or award Common Stock | +2,600 | $0.00 | $0 | 8,510,495 | Jan 6, 2025 |
| Jan 2, 2025 | RNAC Cartesian Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +7,800 | $0.00 | $0 | 7,800 | Jan 6, 2025 |
| Dec 19, 2024 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +11,303 | $17.39 | $197k | 8,467,009 | Dec 23, 2024 |
| Dec 19, 2024 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +10,529 | $18.35 | $193k | 8,477,538 | Dec 23, 2024 |
| Dec 19, 2024 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +3,376 | $18.93 | $64k | 8,480,914 | Dec 23, 2024 |
| Dec 20, 2024 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +21,800 | $18.94 | $413k | 8,502,714 | Dec 23, 2024 |
| Dec 23, 2024 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +5,181 | $19.00 | $98k | 8,507,895 | Dec 23, 2024 |
| Nov 14, 2024 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +74,157 | $16.19 | $1.2M | 8,097,923 | Nov 18, 2024 |
| Nov 14, 2024 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +22,242 | $16.97 | $377k | 8,120,165 | Nov 18, 2024 |
| Nov 15, 2024 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +277,246 | $17.09 | $4.7M | 8,397,411 | Nov 18, 2024 |
| Nov 18, 2024 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +38,114 | $17.96 | $684k | 8,435,525 | Nov 18, 2024 |
| Nov 18, 2024 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +20,181 | $18.42 | $372k | 8,455,706 | Nov 18, 2024 |
| Oct 22, 2024 | TECX Tectonic Therapeutic, Inc. | POpen-market purchase Common Stock | +300,000 | $33.59 | $10M | 4,096,764 | Oct 24, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.